Clatot, F., Perdrix, A., Beaussire, L., Lequesne, J., Lévy, C., Emile, G., . . . Di Fiore, F. (2020). Risk of early progression according to circulating ESR1 mutation, CA-15.3 and cfDNA increases under first-line anti-aromatase treatment in metastatic breast cancer. Breast Cancer Res.
استشهاد بنمط شيكاغوClatot, Florian, et al. "Risk of Early Progression According to Circulating ESR1 Mutation, CA-15.3 and CfDNA Increases Under First-line Anti-aromatase Treatment in Metastatic Breast Cancer." Breast Cancer Res 2020.
MLA استشهادClatot, Florian, et al. "Risk of Early Progression According to Circulating ESR1 Mutation, CA-15.3 and CfDNA Increases Under First-line Anti-aromatase Treatment in Metastatic Breast Cancer." Breast Cancer Res 2020.